Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients - PubMed

Review

Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients

Anders Asberg. Drugs. 2003.

Abstract

Dyslipidaemia is more frequent in solid organ transplant recipients than in the general population, primarily as a result of immunosuppressive drug treatment. Both cyclosporin and corticosteroids are associated with dyslipidaemic adverse effects. In order to reduce the overall cardiovascular risk in these patients, lipid-lowering drugs have become widely used, especially HMG-CoA reductase inhibitors (statins). Cyclosporin, as well as most statins (lovastatin, simvastatin, atorvastatin and pravastatin) are metabolised by cytochrome P450 (CYP)3A4, so a bilateral pharmacokinetic interaction between these drugs is theoretically possible. However, results from several studies show that statins do not induce increased systemic exposure of cyclosporin. A small (but not clinically relevant) reduction in systemic exposure of cyclosporin has actually been shown in many studies. Cyclosporin-treated patients on the other hand show several-fold higher systemic exposure of all statins, both those that are metabolised by CYP3A4 and fluvastatin (metabolised by CYP2C9). Therefore, the mechanism for this interaction does not seem to be solely caused by inhibition of CYP3A4 metabolism, but it is probably also a result of inhibition of statin-transport in the liver, at least in part. Other lipid-lowering drugs, such as fibric acid derivatives, bile acid sequestrants, probucol, fish oils and orlistat are also used in solid organ transplant recipients. Most of them do not interact with cyclosporin, but there are reports indicating that both probucol and orlistat may reduce cyclosporin bioavailablility to a clinically relevant degree. There is no information on possible interaction effects of cyclosporin on the pharmacokinetics of lipid-lowering drugs other than statins, but it is not likely that any clinical relevant interference exists with fish oil, orlistat, probucol or bile acid sequestrants.

Similar articles

• Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

  Williams D, Feely J. Williams D, et al. Clin Pharmacokinet. 2002;41(5):343-70. doi: 10.2165/00003088-200241050-00003. Clin Pharmacokinet. 2002. PMID: 12036392 Review.

• [Metabolic interactions with statins].

  Molden E, Asberg A. Molden E, et al. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93. Tidsskr Nor Laegeforen. 2001. PMID: 11475198 Review. Norwegian.

• Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

  Neuvonen PJ, Niemi M, Backman JT. Neuvonen PJ, et al. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003. Clin Pharmacol Ther. 2006. PMID: 17178259 Review.

• Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

  Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Rätz Bravo AE, et al. Drug Saf. 2005;28(3):263-75. doi: 10.2165/00002018-200528030-00007. Drug Saf. 2005. PMID: 15733030

• Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

  Lennernäs H, Fager G. Lennernäs H, et al. Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.

Cited by

• Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

  Bourgoin H, Paintaud G, Büchler M, Lebranchu Y, Autret-Leca E, Mentré F, Le Guellec C. Bourgoin H, et al. Br J Clin Pharmacol. 2005 Jan;59(1):18-27. doi: 10.1111/j.1365-2125.2005.02200.x. Br J Clin Pharmacol. 2005. PMID: 15606436 Free PMC article.

• Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

  Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Pisano G, et al. World J Gastroenterol. 2016 Oct 28;22(40):8869-8882. doi: 10.3748/wjg.v22.i40.8869. World J Gastroenterol. 2016. PMID: 27833378 Free PMC article. Review.

• Treatment of Dyslipidemia in Common Liver Diseases.

  Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Speliotes EK, et al. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1189-1196. doi: 10.1016/j.cgh.2018.04.023. Epub 2018 Apr 21. Clin Gastroenterol Hepatol. 2018. PMID: 29684459 Free PMC article. Review. No abstract available.

• Metabolic and cardiovascular complications in the liver transplant recipient.

  Luca L, Westbrook R, Tsochatzis EA. Luca L, et al. Ann Gastroenterol. 2015 Apr-Jun;28(2):183-192. Ann Gastroenterol. 2015. PMID: 25830307 Free PMC article. Review.

• [Sequelae of organ transplantation].

  Ciesek S, Manns M, Strassburg C. Ciesek S, et al. Internist (Berl). 2006 Mar;47(3):252, 254-6, 258-60 passim. doi: 10.1007/s00108-006-1583-1. Internist (Berl). 2006. PMID: 16470354 German.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information